Unlicensed Cannabis Products in New York Contaminated with Harmful Substances

Dec.02.2022
Unlicensed Cannabis Products in New York Contaminated with Harmful Substances
An industry report found illegal marijuana sales in New York contain harmful bacteria, heavy metals, and toxic pesticides.

A report released on Wednesday reveals that some marijuana products sold in unlicensed stores in New York are not only illegal but contaminated with harmful bacteria, heavy metals, and toxic pesticides.


The association conducted laboratory tests on smokable cannabis, edible candies, and vaporizers purchased from 20 tobacco shops and pharmacies. They found eight different contaminants, including E. coli, salmonella, nickel, and lead, which are prohibited. According to a report from the New York Medical Marijuana Industry Association, a state trade organization, the investigation also revealed that some products had incorrect labeling of their strength.


The association represents licensed healthcare pharmacy operators in New York. It stated that the investigation's results highlight the concerns of elected officials and regulatory agencies regarding the danger posed by the reckless growth of retail stores in the state, which falsely claim that their products are legal.


At present, legal sales of marijuana in New York are limited to patients of 38 medical dispensaries operated by the association. However, prior to the release of this report, regulatory authorities granted licenses to 36 retail dispensaries in the state's first batch of approvals. The regulatory authorities stated that legal sales of recreational marijuana will begin in December.


The industry association stated in its report that "just as the imperial government was preparing to achieve this important goal, new illegal operators have emerged, seizing the tail of the highly respected legacy market, endangering public health and safety as well as the long-term success of legitimate operators.


For years, medical pharmacy operators have been frustrated by their exclusion from the New York retail market due to the prevalence of unlawful storefronts operating without regulation or repercussions. The report aims to pressure authorities to restrict illegal sales, as the healthcare industry seeks modifications to proposed regulations that would require them to pay at least $3 million to enter the retail market.


According to laboratory results, these tests were authorized by Curaleaf, a national chain with four locations in New York, currently facing fines, lawsuits, and product recalls in at least five states as well as license revocations in Oregon.


In Kura Sushi's statement, it defended the reputation of the company by pointing out that the suspension in Oregon is the first time in the 12 years of operation of the chain. A senior female spokesperson stated that this incident involves mislabeled products, and the discovery proves that supervision of the industry is working and regulatory agencies are also taking note of the company's cooperation.


She said that illegal markets in New York or any other state do not have this type of regulatory mechanism.


A newspaper has obtained a report from a basic laboratory test, but no independent verification of any testing results has been completed. Experts advise caution when interpreting these findings, noting that bacteria die when exposed to smoke and some metals and pesticides are considered safe in low amounts. Officials from the city government and cannabis regulatory agencies have stated that they are reviewing the report.


Overall, tests revealed that 16 out of 40 products were found to contain pollutants. Nine products contained tetrahydrocannabinol (THC), the intoxicating compound found in marijuana, at levels lower than what was advertised on their labels. However, analysis showed that one type of gummy candy claimed to have 100 milligrams of THC per piece on its label, but actually contained twice that amount.


The most common pollutants found in cannabis products are Escherichia coli and Salmonella, which were detected in nine different items, particularly loose bud and pre-rolled joints. National regulations prohibit the sale of cannabis products contaminated with these bacteria to consumers. Both types of bacteria can cause infections, often resulting in symptoms such as diarrhea, vomiting, fever, and cramps. In severe cases, they can be life-threatening.


The CEO of Talon Analytical, a laboratory licensed by the state, Michael Bianco, has stated that the tested products do not meet the standards set in New York. The company has tested illegal products for their clients, which are mostly medical marijuana companies.


The spokesperson for the Cannabis Control Office, Aaron Ghitelman, stated that the report confirms officials' long-standing claims about the risks of unregulated products and the necessity of shutting down unlicensed storefronts. The agency's governing board passed regulation last week denying licenses to individuals who sell marijuana in unlicensed storefronts or vehicles, or in any other way falsely claiming to be operating legally.


The office is currently involved in a cross-departmental joint law enforcement pilot with the city. Mayor Eric Adams has stated that this initiative has resulted in the confiscation of over 100,000 items and the issuance of 300 civil and criminal violations.


Officials did not indicate whether they will take action against any specific companies that were involved in the sale of tested products mentioned in the report.


2FIRSTS will continue to provide updates on this issue, with further information available on the '2FIRSTS APP'. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
DOJO officially launched the BLAST7K Fresh on September 17, 2026, introducing a UK-market prefilled pod product with 6ml of e-liquid and a manufacturer-rated capacity of up to 7,000 puffs. The device features a 1000mAh rechargeable battery, the INSTA-JUICED structure and COREX BLAST dual-mesh technology, while retaining compatibility with existing BLAST pods. The launch comes less than two weeks before the UK's Vaping Products Duty takes effect on October 1. At the new duty rate, 6ml of vaping liquid would correspond to £1.32 in VPD. DOJO has not stated that the product's 6ml format was designed in response to the new duty.
Sep.20
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives